TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07595367: Evaluate the Effectiveness and Safety of BBD-1 Multi-target Immune Enhancement Targeting Agent in the Treatment of Hypersensitivity Reaction (IgA) Vasculitis

Sponsor: Qifeng Zhang · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$2,415,000

Rescue Site Savings

+$1,587,000

Unlock Full NCT07595367 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07595367 Rescue Dossier →